Our Technology Transfer Support Includes
Upon procurement of our liposomal APIs, we deliver comprehensive dosage form conversion and technology transfer support, enabling seamless transformation of the active into scientifically optimised, stable, and commercially scalable finished dosage forms for pharmaceutical and nutraceutical applications. Our support covers formulation strategy, process parameter optimisation, manufacturing adaptability, and regulatory-ready development to ensure accelerated product commercialisation with consistent quality and performance.
Dosage Form Development Support
- Tablet formulation development: Advanced optimisation of direct compression, wet granulation, and dry granulation, achieving superior powder flowability, compressibility, and hardness control.
- Capsule formulation systems: Precision-filled hard gelatin or HPMC systems with optimised bulk density, blend homogeneity, and fill weight accuracy, preventing segregation.
- Pellet formulation engineering: Multiparticulate systems using extrusion-spheronization, powder layering for controlled release, enhanced bioavailability, superior GI targeting.
- Granule and sachet development: Free-flowing granulated systems with optimised particle distribution, moisture barrier protection, and dispersibility ensuring precise unit-dose delivery.
Liquid & Specialised Systems
- Oral liquid suspension development: Stabilisation of liposomal dispersions through viscosity modulation, sedimentation control, particle size stabilisation, and preservative system compatibility.
- Syrup and emulsion formulation: Homogeneous emulsion-based systems with improved palatability, phase stability, droplet size control, oxidative protection, and enhanced bioavailability.
- Effervescent formulation support: Highly stable delivery systems with controlled acid-base reactivity, moisture sensitivity management, rapid dissolution, and optimised carbon dioxide release.
- Powder blend stick pack development: Stable powder premixes with superior flow properties, anti-segregation control, instant dispersion performance, and hygroscopicity management.
Advanced Release Systems
- Enteric-coated formulation support: pH-dependent enteric protection using advanced polymer engineering, preventing gastric degradation, protecting liposomal membrane integrity.
- Sustained release controlled systems: Release-modulated platforms through hydrophilic/hydrophobic polymer matrix engineering, diffusion controlling prolonged therapeutic efficacy.
- GI-targeted intestinal release: Strategic GI-bypass delivery utilising delayed-release, pH-responsive, site-specific mechanisms maximising intestinal absorption, minimising gastric degradation.
- Coating system development: Optimisation of barrier coatings, enteric coatings, sustained-release layers, improving moisture resistance, oxidation control, and release modulation.
Scientific Selection & Compatibility
- Dosage form selection guidance: Comprehensive evaluation of liposomal API physicochemical attributes, particle size distribution, and zeta potential, determining suitable scalable architecture.
- Excipient compatibility selection: Rational selection of binders, diluents, stabilisers, surfactants, lubricants, preservatives, and coating polymers based on compatibility studies.
- Biopharmaceutical performance optimisation: Assessment of encapsulation efficiency, release kinetics, biopharmaceutical performance, target application requirements, and ensuring commercial viability.
- Formulation stability enhancement: Long-term physicochemical stability improvement through strategic component selection and process optimisation, maintaining liposomal structural integrity.
Parameter Optimisation & Protocols
- Critical process parameter standardisation: Scientific standardisation of CPPs and CQAs, including mixing efficiency, granulation endpoint, drying kinetics, and coating uniformity.
- Manufacturing process transfer: Seamless transfer of validated formulation processes, technology packages, batch manufacturing protocols, standard operating parameters.
- Pilot batch execution support: Technical supervision of pilot-scale manufacturing trials verifying formulation robustness, process feasibility, and equipment suitability.
- Scale-up commercial validation: Scientific scale-up execution with validation of process reproducibility, batch-to-batch consistency, in-process controls, and GMP compliance.
Precision Scale-Up Protocols
- Shear rate optimisation: Exact RPM and duration settings for high-speed homogenisers, defining precise energy input in the nanometer range without over-shearing.
- Sonication parameter control: Detailed amplitude and pulse-cycle instructions ensuring uniform particle distribution, preventing hotspots leading to ingredient degradation.
- Temperature control profiles: Exact cooling curves and phase-addition temperatures required for incorporating heat-sensitive actives without compromising molecular potency.
- Hardware compatibility guidance: Engineering assessment ensuring existing equipment meets nanotechnology demands through gap analysis and inline processing design optimisation
Process & Manufacturing Transfer – Quality Control Integration
- Real-time transparency monitoring: Benchmarks for turbidity and refractive index testing, enabling manufacturing teams to verify batch quality in real time.
- Batch-to-batch consistency protocols: Defining Critical Quality Attributes, ensuring the first batch is identical to the thousandth batch with no drift in viscosity, pH, porosity, and particle size diffusion verification: Instructions for simplified diffusion models that ensure sustained release, validated in labs and achieved in every production run.
- Equipment material geometry: Optimal tank shapes and contact materials that prevent the adsorption of premium lipids, ensuring maximum yield and cost-efficiency.
Training & Troubleshooting Support
- On-site remote training: Education of production chemists and operators on the unique behaviour of purified saturated phospholipids and high-potency actives.
- Troubleshooting decision trees: Blueprints for common manufacturing hurdles, including aeration, ionic balance, and viscosity changes, allowing instant issue resolution.
- Commercial advantage optimisation: Reduction of time-to-market through elimination of trial-and-error phases, preventing costly batch failures.
- Manufacturing team empowerment: Comprehensive knowledge transfer ensuring teams can maintain scientific potency from the research facility through consumer delivery.
Analytical, Regulatory & Commercialisation Support – Method Development
- Analytical method validation: Development and validation of protocols for assay, dissolution profiling, encapsulation efficiency, particle size analysis, and zeta potential.
- Release study optimisation: SGF/SIF/SSF release studies, oxidative stability assessment, accelerated stability evaluation, and ensuring comprehensive product characterisation.
- Stability testing protocols: Long-term and accelerated stability programs establishing shelf-life specifications and storage condition requirements.
- Quality control transfer: Implementation of analytical rigour mirroring laboratory standards, ensuring consistent quality assessment during commercial production.
Analytical, Regulatory & Commercialisation Support
- GMP documentation preparation: Comprehensive technical dossiers including MFR, BMR, SOPs, specifications, validation protocols, process flow sheets.
- Regulatory submission support: Development reports and regulatory submission documentation for global compliance readiness across pharmaceutical and nutraceutical sectors.
- Commercialisation readiness alignment: Final technical verification for successful market launch through process robustness verification, production scalability assessment.
- Validation closure support: Complete validation documentation ensuring audit readiness, compliance assurance, and uninterrupted commercial supply chain continuity.
Analytical, Regulatory & Commercialisation Support – Manufacturing Excellence
- Cleaning validation protocols: Comprehensive cleaning procedures ensuring cross-contamination prevention and equipment suitability for liposomal production.
- Process reproducibility verification: Statistical process control implementation ensuring consistent quality output across production batches and manufacturing campaigns.
- Commercial supply chain readiness: Final alignment ensuring seamless transition from development through commercial production with sustained quality standards.
- Global compliance framework: Documentation and process alignment supporting market entry across diverse regulatory environments and international quality requirements.
Technology Transfer Challenges We Resolve
Transition from laboratory beaker to industrial tank, maintaining transparency, stability, efficacy through precision process replication.
Hardware gap analysis and engineering guidance ensuring existing equipment meets nanotechnology manufacturing demands.
Exact translation of lab-scale supremacy to factory floor, maintaining particle size and sustained-release profile integrity.
Transfer of analytical rigour, ensuring on-site QC protocols mirror laboratory standards for real-time batch verification.
Manufacturing Transfer Troubleshooting
Phospholipid bilayer destruction, transparency loss, vesicle instability corrected through RPM optimisation
Heat-sensitive active degradation, molecular potency loss prevented through thermal profiling protocols
Viscosity drift, pH changes, particle size inconsistency resolved through CQA standardisation
Homogeniser inadequacy, processing limitations overcome through engineering assessment and modification
Real-time monitoring failures, batch rejection risks minimised through turbidity and refractive index benchmarking
Technology Transfer & Scale-up Readiness
Comprehensive evaluation of liposomal API characteristics determining optimal dosage form architecture based on physicochemical properties, target applications, and commercial scalability requirements.
Scientific standardisation of critical parameters, manufacturing protocols, and quality control systems ensures reproducible commercial production with validated batch-to-batch consistency.
Engineering evaluation of existing manufacturing infrastructure, with optimisation recommendations to ensure hardware compatibility with liposomal technology requirements.
Complete preparation of GMP-compliant documentation, validation protocols, and regulatory submission packages supporting global market authorisation and commercial launch.
Why Partner with Lipoedge for Technology Transfer
Seamless transformation of liposomal APIs into scientifically optimised, stable, commercially scalable finished dosage forms across all platforms.
Precision optimisation of encapsulation efficiency, particle distribution, zeta potential, and release kinetics, ensuring enhanced bioavailability and reliability.
Development of enteric-coated, sustained-release, pH-responsive platforms protecting membrane integrity with precise intestinal targeting.
End-to-end transfer of validated processes, critical parameters, and quality attributes, ensuring accurate pilot-to-commercial execution.
Comprehensive GMP preparation, including MFR, BMR, SOPs, and validation protocols, ensuring full compliance and global acceptance.
Ready to Elevate Your
Formulation Testing?
Partner with LipoEdge's expert scientific team for end-to-end in vitro analytical support — from study design to regulatory submission.
Frequently Asked Questions
In vitro chemical testing generates release, stability, and bioaccessibility data, enabling informed formulation decisions across nutraceutical, pharmaceutical, and cosmeceutical product development pipelines. This reduces development uncertainty, supports faster optimisation of dosage forms, and strengthens technical confidence before scale-up, validation, and regulatory submission stages.
The INFOGEST model simulates human digestion conditions across salivary, gastric, and intestinal phases, enabling realistic evaluation of liposomal stability and release behaviour. It helps predict oral bioavailability, validate formulation performance under physiological conditions, and support scientifically substantiated claims for product positioning and regulatory documentation.
Dialysis and simulated digestion studies quantify controlled release behaviour, enabling clear differentiation between liposomal systems and conventional formulations in performance-driven markets. This supports claims of sustained delivery, improved absorption, and enhanced functionality, strengthening product positioning across competitive nutraceutical and pharmaceutical segments globally.
LipoEdge provides integrated in vitro testing using validated digestion models, diffusion systems, and antioxidant assays to ensure reliable and reproducible analytical outcomes. It enables clients to generate regulatory-aligned data, optimise formulations effectively, and accelerate product development timelines with strong technical and commercial confidence.
LipoEdge combines formulation understanding with analytical expertise, enabling customised study designs tailored to liposomal, nanosomal, and encapsulated delivery systems across applications. This ensures deeper insight into product behaviour, improved interpretation of results, and stronger alignment between laboratory findings and real-world product performance expectations.